|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
self-injection
|
|
gptkbp:approvalRegion
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:approvalYear
|
2018-08-23
|
|
gptkbp:ATCCode
|
B06AC05
|
|
gptkbp:CASNumber
|
1428907-60-6
|
|
gptkbp:form
|
solution for injection
300 mg/2 mL
|
|
gptkbp:frequency
|
every 2 weeks
every 4 weeks (for some patients)
|
|
gptkbp:genericName
|
lanadelumab
|
|
gptkbp:halfLife
|
14 days
|
|
gptkbp:hasMolecularFormula
|
C6428H9956N1720O2016S44
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TAKHZYRO
|
|
gptkbp:indication
|
gptkb:hereditary_hemorrhagic_telangiectasia
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Takeda_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
plasma kallikrein inhibitor
|
|
gptkbp:pregnancyCategory
|
not assigned
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
dizziness
headache
injection site reaction
rash
upper respiratory infection
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:target
|
plasma kallikrein
|
|
gptkbp:type
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsParent
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:bfsLayer
|
7
|